Ensign Peak Advisors
RMD icon

Ensign Peak Advisors’s ResMed RMD Stock Holding History

Ensign Peak Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.23M Sell
42,238
-6,860
-14% -$1.42M 0.01% 471
2026
Q1 		$11M Buy
49,098
+6,689
+16% +$1.67M 0.02% 392
2025
Q4 		$10.2M Sell
42,409
-18,836
-31% -$4.82M 0.02% 405
2025
Q3 		$16.8M Sell
61,245
-21,951
-26% -$6M 0.03% 344
2025
Q2 		$21.5M Sell
83,196
-7,021
-8% -$1.67M 0.04% 304
2025
Q1 		$20.2M Sell
90,217
-4,692
-5% -$1.1M 0.04% 303
2024
Q4 		$21.7M Sell
94,909
-211
-0.2% -$50.8K 0.04% 306
2024
Q3 		$23.2M Buy
95,120
+9,410
+11% +$2.1M 0.04% 296
2024
Q2 		$16.4M Buy
85,710
+13,324
+18% +$2.7M 0.03% 345
2024
Q1 		$14.3M Buy
72,386
+19,829
+38% +$3.63M 0.03% 382
2023
Q4 		$9.04M Buy
52,557
+42,571
+426% +$6.54M 0.02% 461
2023
Q3 		$1.48M Sell
9,986
-66
-0.7% -$11.9K ﹤0.01% 945
2023
Q2 		$2.2M Sell
10,052
-2,867
-22% -$639K ﹤0.01% 838
2023
Q1 		$2.83M Hold
12,919
– – 0.01% 723
2022
Q4 		$2.69M Buy
12,919
+150
+1% +$33K 0.01% 724
2022
Q3 		$2.79M Sell
12,769
-600
-4% -$137K 0.01% 675
2022
Q2 		$2.8M Buy
13,369
+1,318
+11% +$281K 0.01% 691
2022
Q1 		$2.92M Sell
12,051
-1,119
-8% -$271K 0.01% 734
2021
Q4 		$3.43M Sell
13,170
-2,666
-17% -$692K 0.01% 778
2021
Q3 		$4.17M Buy
15,836
+397
+3% +$109K 0.01% 730
2021
Q2 		$3.81M Sell
15,439
-3,405
-18% -$716K 0.01% 767
2021
Q1 		$3.66M Sell
18,844
-6,347
-25% -$1.27M 0.01% 771
2020
Q4 		$5.35M Sell
25,191
-5,035
-17% -$1M 0.01% 586
2020
Q3 		$5.18M Buy
30,226
+12,365
+69% +$2.28M 0.01% 621
2020
Q2 		$3.43M Buy
17,861
+250
+1% +$40.9K 0.01% 724
2020
Q1 		$2.59M Sell
17,611
-5,900
-25% -$940K 0.01% 725
2019
Q4 		$3.64M Buy
+23,511
New +$3.39M 0.01% 752

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ensign Peak Advisors's RMD Position: Q2 2026 in Review

Ensign Peak Advisors reduced its ResMed (RMD) stake by 14% in Q2 2026, selling an estimated $1.42M and leaving 42,238 shares worth $8.23M. The position accounts for 0.01% of the portfolio, ranked #471.

Ensign Peak Advisors first reported a position in RMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $23.2M in Q3 2024. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Ensign Peak Advisors held 42,238 shares of ResMed worth $8.23M as of Q2 2026.
  • Ensign Peak Advisors sold 6,860 ResMed shares in Q2 2026, an estimated $1.42M.
  • ResMed made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #471 holding.
  • Ensign Peak Advisors first reported a position in ResMed in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's ResMed position peaked at $23.2M in Q3 2024.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.